Adult Immunization

Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."

Neutralizing antibodies were lowest among Janssen volunteers at 1 month post-vaccination but at 6 months afterward, the picture was much different.

New CDC recommendations for pneumococcal vaccination for persons aged 19 to 64 years could require some extra thought. This 4-question quiz tests your knowledge.

Reducing American's risk for CHD and cardiovascular events gets harder as the population ages and obesity rates climb. Can a vaccine help?

Tirzepatide delivers 15.7% weight loss in adults with obesity; remote intervention increases cancer screening in women; women at greater post-MI risk vs men; plus 2 more updates of note.

The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.

The FDA action ends the use of monovalent COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna in favor of bivalent formulations to simplify the vaccination schedule, said the Agency.

Ensitrelvir fast track status is supported by phase 3 study findings showing resolution of COVID-19 symptoms a full day earlier in those taking the drug vs placebo.

Onset of the 2022-2023 RSV season and its end were closer to historical patterns but atypical circulation may continue, say researchers writing in MMWR.

Vaccine side effects are usually trouble when they make the news. But sometimes, an unexpected result has merit. Find out more.

Universal vaccination against chickenpox with a live-attenuated varicella vaccine began 25 years ago. Were concerns about future shingles outbreaks borne out?

Your daily dose of clinical news you may have missed.

Research on myocarditis has found the risk for the condition significantly higher from infection with SARS-CoV-2 vs from mRNA vaccination against it. True or False?

For vaccine-hesitant patients concerned about myocarditis, it may be helpful to provide real-world context. The quiz contains tips on how to do that.

ACC 2023. Electronic nudges highlighting the potential cardiovascular benefits of flu vaccination led to a modest uptake in vaccination rates among older adults in Denmark, according to results of the NUDGE-FLU trial.

Data presented at CROI 2023 demonstrated that periods of reinfection with the virus correlated with ascent of new variants and with time since first infection.

The VRBPAC vote that the GSK data support the vaccine's efficacy was unanimous and on safety the vote was 10-2. PDUFA date set for May, 2023.

The study of more than 1.9 million US residents is the first to investigate a link between both full and partial COVID-19 vaccination and future CV risk.

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

The large biobank-based study found 22 pairings of a neurodegenerative disorder and a previous viral infection. Vaccines exist against several of those viruses.

The EHR analysis found greater risk of type 2 diabetes after COVID regardless of vaccination status although odds were greater for those unvaccinated before infection.

Get a quick topline look at specific revisions and additions included in the ACIP's recommendations for routine immunization of those aged ≥19 years in the US.

Administering multiple vaccines at the same visit is shown to increase vaccination rates but is not always advisable. Try this quiz on 2 clinical scenarios.

Lotteries with cash incentives and other giveaways are just one example of ways the COVID-19 pandemic changed the way US health care is handled.

These tips from a family physician on managing misinformation in the exam room can help reduce the spread of false and misleading narratives.

The Kaiser Family Foundation survey found a 10% drop in the proportion of adults who say MMR vaccination should be required for school attendance, and other "halo" effects.

Preliminary estimates showed relative bivalent booster dose vaccine effectiveness against XBB/XBB.1.5 for at least the first 3 months after vaccination.

The mRNA vaccine returned efficacy of 83.7% against RSV-associated lower respiratory tract disease defined by ≥2 symptoms and of 82.4% against disease defined by ≥3 symptoms.

Overall dyspnea was the most common symptom of long COVID in the first year after infection, according to the nationwide retrospective cohort study.